Aspira Women's Health Inc. (AWHL) stock
AWHLOTCIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
$0.22−0.01 (-2.61%)
Close on Oct 19, 2026Market cap $9.91MP/E –Yield –
Aspira Women's Health r&d expenses
Research and development expenses are spending on new products and technology.
Aspira Women's Health's R&D Expenses for the twelve months ending Jun 30, 2026 was $3.12M, up 1.1% year over year. For fiscal 2025 it was $2.88M, down 11.9% from the year before. Over ten years it grew -2.6% a year on average. The highest annual figure on record is $5.92M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.88M | -11.9% |
| FY2024 | Dec 31, 2024 | $3.27M | -19.1% |
| FY2023 | Dec 31, 2023 | $4.04M | -31.8% |
| FY2022 | Dec 31, 2022 | $5.92M | +11.3% |
| FY2021 | Dec 31, 2021 | $5.31M | +152.6% |
| FY2020 | Dec 31, 2020 | $2.10M | +106.7% |
| FY2019 | Dec 31, 2019 | $1.02M | +85.1% |
| FY2018 | Dec 31, 2018 | $550.00K | -34.3% |
| FY2017 | Dec 31, 2017 | $837.00K | -61.5% |
| FY2016 | Dec 31, 2016 | $2.17M | -42.1% |
| FY2015 | Dec 31, 2015 | $3.75M | -19.6% |
| FY2014 | Dec 31, 2014 | $4.67M | +79.8% |
| FY2013 | Dec 31, 2013 | $2.60M | +17.1% |
| FY2012 | Dec 31, 2012 | $2.22M | -58.9% |
| FY2011 | Dec 31, 2011 | $5.39M | +40.0% |
| FY2010 | Dec 31, 2010 | $3.85M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $692.00K | -1.7% |
| Q1 FY2026 | Mar 31, 2026 | $1.23M | +26.0% |
| Q4 FY2025 | Dec 31, 2025 | $462.00K | -7.6% |
| Q3 FY2025 | Sep 30, 2025 | $739.00K | -18.6% |
| Q2 FY2025 | Jun 30, 2025 | $704.00K | -26.1% |
| Q1 FY2025 | Mar 31, 2025 | $973.00K | +7.4% |
| Q4 FY2024 | Dec 31, 2024 | $500.00K | -53.6% |
| Q3 FY2024 | Sep 30, 2024 | $908.00K | -9.0% |
| Q2 FY2024 | Jun 30, 2024 | $952.00K | +37.4% |
| Q1 FY2024 | Mar 31, 2024 | $906.00K | -28.5% |
| Q4 FY2023 | Dec 31, 2023 | $1.08M | +7.5% |
| Q3 FY2023 | Sep 30, 2023 | $998.00K | -53.7% |
| Q2 FY2023 | Jun 30, 2023 | $693.00K | -50.9% |
| Q1 FY2023 | Mar 31, 2023 | $1.27M | -6.0% |
| Q4 FY2022 | Dec 31, 2022 | $1.00M | -31.0% |
| Q3 FY2022 | Sep 30, 2022 | $2.16M | +42.1% |
| Q2 FY2022 | Jun 30, 2022 | $1.41M | -4.1% |
| Q1 FY2022 | Mar 31, 2022 | $1.35M | +54.6% |
| Q4 FY2021 | Dec 31, 2021 | $1.45M | +98.0% |
| Q3 FY2021 | Sep 30, 2021 | $1.52M | +155.1% |
| Q2 FY2021 | Jun 30, 2021 | $1.47M | +287.1% |
| Q1 FY2021 | Mar 31, 2021 | $872.00K | +120.8% |
| Q4 FY2020 | Dec 31, 2020 | $734.00K | +200.8% |
| Q3 FY2020 | Sep 30, 2020 | $595.00K | +75.0% |
| Q2 FY2020 | Jun 30, 2020 | $380.00K | +68.9% |
| Q1 FY2020 | Mar 31, 2020 | $395.00K | +89.0% |
| Q4 FY2019 | Dec 31, 2019 | $244.00K | +95.2% |
| Q3 FY2019 | Sep 30, 2019 | $340.00K | +163.6% |
| Q2 FY2019 | Jun 30, 2019 | $225.00K | +46.1% |
| Q1 FY2019 | Mar 31, 2019 | $209.00K | +47.2% |
| Q4 FY2018 | Dec 31, 2018 | $125.00K | -17.8% |
| Q3 FY2018 | Sep 30, 2018 | $129.00K | -32.8% |
| Q2 FY2018 | Jun 30, 2018 | $154.00K | -42.5% |
| Q1 FY2018 | Mar 31, 2018 | $142.00K | -36.9% |
| Q4 FY2017 | Dec 31, 2017 | $152.00K | -50.0% |
| Q3 FY2017 | Sep 30, 2017 | $192.00K | -48.1% |
| Q2 FY2017 | Jun 30, 2017 | $268.00K | – |
| Q1 FY2017 | Mar 31, 2017 | $225.00K | – |
| Q4 FY2016 | Dec 31, 2016 | $304.00K | – |
| Q3 FY2016 | Sep 30, 2016 | $370.00K | – |
See a number that looks wrong?